Fierce Biotech April 7, 2024
Three years after receiving BioNTech’s cancer vaccine in a phase 1 trial, patients with a difficult-to-treat type of pancreatic cancer continue to have T-cell responses.
Meanwhile, the German mRNA company is enrolling a phase 2 test of the therapy, autogene cevumeran, in the same disease, resected pancreatic ductal adenocarcinoma (PDAC).
PDAC has a five-year overall survival rate of about 8% to 10% and recurrence rates as high as 80% after surgery. BioNTech and partner Genentech are hoping to provide another option for patients who have few with autogene cevumeran (also known as BNT122 and RO7198457). The med is an mRNA-based individualized neoantigen-specific immunotherapy.
The long-term follow-up data from the early-stage trial shows that eight out of 16 patients continue to...
Today's Sponsors
Today's Sponsor